Introduction
When large volume seminoma is treated with cisplatinbased chemotherapy cure rates are high, yet computed tomographic (CT) scans will demonstrate a residual mass in one-third to two-thirds of patients [1] [2] [3] [4] [5] . Recurrences after cisplatin chemotherapy occur in 10%-20% of patients [6] [7] [8] , and there is controversy over whether recurrence probability is linked to the presence or size of any residual mass following chemotherapy. We have previously analysed patterns of recurrence after single agent carboplatin for advanced seminoma and found suggestive evidence that post-chemotherapy radiation of residual masses may reduce the risk of recurrence [2] . However, there is less evidence for this following cisplatin-based combination chemotherapy [3, 7] . We have, therefore, analysed the pattern of response to cisplatin-based combination chemotherapy in 45 patients with advanced seminoma, 18 of whom also had post-chemotherapy irradiation.
Patients and methods
Between October 1978 and May 1994, 45 patients were treated with cisplatin-based chemotherapy for advanced seminoma within the Testicular Tumour Unit of the Royal Marsden Hospital. No patients had received previous chemotherapy but 11 had had prior abdominal radiotherapy for stage I, stage IIA or stage IIB seminoma and were treated with chemotherapy for relapse. Assessment of patients included review of histology, assay of the serum tumour markers, human chorionic gonadotrophin (HCG), and alphafetoprotein (AFP) and computer tomography (CT) of thorax, abdomen and pelvis. The glomerular filtration rate (GFR) was assessed in all patients by excretion of chromium-51 EDTA. The RMH staging classification was applied (Table 1) . Thirtyfive patients had a primary testicular tumour, three had primary mediastinal seminomas and one had an apparent primary site within the prostate. Six patients presented with a retroperitoneal mass which may have either been extragonadal or secondary to occult testicular primary sites. No patients in this series had raised serum AFP concentrations, though 23 had elevated HCG. The series was based on patients with retroperitoneal masses > 5 cm in diameter, supradiaphragmatic nodal metastasis or extra nodal metastasis. We also included one patient with stage IIA disease, treated with chemotherapy because of extensive burn scars in the groin which were felt to be a relative contra indication to radiation, and also one patient, who presented with stage IIB disease whose pattern of spread was atypical and included an enlarged femoral lymph node.
All 45 patients were treated with cisplatin-containing chemotherapy. Treatment practices evolved during the period of this study. Nine patients were treated with cisplatin vinblastine and bleomycin (PVB) [1] , 33 patients were treated with bleomycin, etoposide, cisplatin (BEP) [1] , (eight of whom had one or two additional cycles of either single agent carboplatin, single agent cisplatin or the combination of etoposide and cisplatin), one patient had etoposide and cisplatin and two patients had intensive induction chemotherapy prior to BEP (BOP/BEP) [9] . Following completion of chemotherapy 18 patients had adjuvant radiotherapy to original involved sites based on the presence of residual mass and concern about follow-up. A further five patients had surgical exploration post-chemotherapy, four of whom had a residual mass. In none was there histological evidence of malignancy.
Follow-up from the start of chemotherapy was a median of 146 months (range 10-202 months). Following treatment patients were assessed at three-month intervals for two years, six-month intervals for two years and then annually. The definition of a residual mass was soft tissue demonstrated on CT scan > 1 cm in diameter at the site of the pre-treatment mass. Patients with residual masses untreated following chemotherapy had reassessment scan at 3, 6 and 12 months following chemotherapy and then annually unless the mass had shrunk to < 1 cm in diameter; further scans were then not performed. At all outpatient assessments patients had physical examination and assay of serum levels of AFP and beta-HCG.
All data were collected prospectively and recorded on the Testicular Tumour Clinical Research Computer Database. Categorical data were examined using the chi-square test with Yates correction and where appropriate survival data were analysed using the Kaplan-Meier product limit method.
Results
Of the total group of 45 patients, 41 (91%) are alive, two have died of germ cell cancer (15 and 16 months after chemotherapy) and two of second malignancies (one leiomyosarcoma of the stomach and one chronic myeloid leukaemia, 137 and 22 months after chemotherapy respectively). The patient who developed leiomyoscarcoma had been treated with abdominal radiotherapy for stage I seminoma 11 years earlier. The 5-and 10-year survivals were 93%.
Of the surviving patients, 39 remained continuously disease-free; however, two patients relapsed after chemotherapy but are now in complete remission after second line treatment. Thus, four patients recurred after chemotherapy and their characteristics are shown in Table 2 . chemotherapy after prior irradiation and in 2 of 34 patients who had not received prior radiotherapy. The two recurrences in the group treated with chemotherapy after radiation relapse were the only two patients who died of progressive germ cell cancer in this series.
Response evaluation by CT scan at the end of chemotherapy revealed complete remission in 12 of the 45 patients (27%). This was linked to the maximum diameter of the tumour mass prior to chemotherapy. In the group of nine patients with tumour diameter < 5 cm, seven achieved CR on chemotherapy alone, whereas amongst 34 patients with tumours > 5 cm CR occurred in only five as shown in Table 2 , (in two patients tumour diameter prior to chemotherapy was imprecisely measured).
Of the 12 patients achieving complete response, three had adjuvant radiotherapy to the previously involved site, one had surgical exploration with no evidence of malignancy found, the remainder were observed. None have relapsed.
Of the 33 (73%) patients with residual masses following chemotherapy, four were explored surgically, showing fibrotic masses with no evidence of malignancy. Of the remaining 29 patients, 15 were treated by adjuvant radiotherapy and 14 were managed by observation alone. The analysis of recurrence according to residual mass size in these patients is shown in Table 3 . There was no clear evidence that risk of recurrence was related to the diameter of the residual tumour. Recurrence occurred in 2 of 14 patients managed by observation and in 2 of 15 patients managed by adjuvant radiotherapy. Of those recurring on observation, one was in a previously uninvolved nodal area (porta hepatis) and one was at the site of a 4-cm residual mass and the recurrence was associated with a rise in serum AFP. The patients relapsing after adjuvant radiotherapy both had developed disseminated disease.
Follow-up of residual masses managed by observation showed complete resolution in 3 of 14 cases and persisting masses in the remainder. Of 10 masses monitored following local radiotherapy, four resolved and the remainder appeared stable; resolution in the seven cases was observed after 6, 8, 9, 16, 18 and 39 months from completion of chemotherapy.
Discussion
The history of chemotherapy for seminoma includes evidence of response to alkylating agents [10] ; however, cure Table 4 . Combination chemotherapy for advanced stminoma.
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Fossa et al. [22] Loehrer et al. [8] Gietema et al. [23] Dexeus e al [24] Zinseretal. [21] Clemn et al. [25] Mencel et al [6] Fossa et al. [7] Abbreviations: Ca -carboplatin; P -cisplatin; B -bleomycin; AAdriamycin (doxorubicin); Cy -cyclophosphamide; I -ifosfamide; Vvinblastine; O -vincristine VAB-6 -vinblastine dactmomycin cisplatin bleomycin cyclophosphamide. was uncommon. Subsequently, when the efficacy of vinblastine and bleomycin combinations was illustrated in non-seminomatous tumours, this combination was also investigated in seven patients with metastatic seminoma but with little success [11] . Multidrug therapies such as bleomycin, cyclophosphamide, vincristine, methotrexate and fluorouracil led to response in about 60% of patients; however, long-term disease control occurred in a minority [11] . The major advance in the chemotherapy of seminoma came with the incorporation of cisplatin into the combination of vinblastine and bleomycin [12] . An early multicentre collaborative report based on 80 patients with advanced seminoma indicated that 61 achieved complete response and 71% remained disease-free [13] . Variations of this PVB regimen including the replacement of vinblastine by etoposide have confirmed the high level of cure in advanced metastatic seminoma as illustrated in Table 4 .
An alternative approach to seminoma chemotherapy was based on weekly pulse cisplatin usually combined with cyclophosphamide. This programme from the M.D. Anderson Hospital achieved long-term disease-free survival in 48 of 52 patients [14] . The need for multiagent chemotherapy has been questioned with evaluations of both single agent cisplatin [15] and of carboplatin [2] . Approximately, 75%-80% of patients appeared to remain free from disease after single agent therapy with again a high level of success in the salvage of relapsing patients. A Medical Research Council trial has compared single agent carboplatin with the combination of cisplatin and etoposide (EP), and a preliminary analysis revealed 13 of 64 patients progressing after single agent carboplatin (Ca) compared to 11 of 66 patients treated with etoposide, cisplatin [16] . Overall survival at two years was 89% for Ca and 91% for EP; however, the size of this trial did not permit treatment outcomes to be judged equivalent and combination chemotherapy based on cisplatin remains the standard approach at present. Table 4 places our results in context of others recently reported in the literature. It can be seen that long-term survival can be expected in between 82% and 93% of patients. Recurrence after initial cisplatin-based combination chemotherapy occurs in 10%-22% of patients, but it is clear that a significant number of these patients can be salvaged with further treatment. In this context, it has recently been demonstrated that ifosfamide-based chemotherapy remains effective in patients who have failed after BEP [17] .
In our view, first line chemotherapy for seminoma should include the combination of etoposide and cisplatin. Though the role of bleomycin is unclear, it probably should be included in more advanced cases such as those presenting with visceral metastases other than in the lung. The majority of patients to be treated with chemotherapy would be appropriate for the current MRC TE20/EORTC 30941 trial in good prognosis germ cell tumour which has its main question the comparison of three cycles of BEP with three cycles of BEP plus one ofEP.
In this paper, we have analysed the pattern of recurrence after combination chemotherapy in relationship to the presence and size of residual mass. The relatively low probability of recurrence reduces the power to detect a significant influence of adjuvant treatments, however, it is notable that two of the four patients in our series who relapsed after chemotherapy had in fact been treated with adjuvant radiotherapy to a residual mass and subsequent relapses were outside the radiation field. A similar pattern has been found in patients recurring after single agent carboplatin when only 7 of 14 recurrences were confined to the originally involved sites [18] . Motzer et al. (1988) [4] reported 4 of 13 residual masses > 3 cm in diameter to contain viable seminoma and a more recent analysis also from the Memorial SloanKettering Cancer Center supported this finding in that involved site failure occurred in only 3% of patients with residual masses < 3 cm in diameter compared to 27% in those ^ 3 cm [19] . The conclusion that bulky residual masses were more likely to contain viable tumour was supported by Fossa et al. (1989) [20] ; however, neither Schultz et al. (1989) [3] , Horwich et al. (1992) [2] nor Zinser et al. (1991) [21] could find a significant relationship between residual mass size and the risk of recurrence. In a recent report of the EORTC study of the combination of cisplatin, vincristine and ifosfamide for metastatic seminoma, Fossa et al. (1995) [7] reported a persisting mass in 16 out of 17 patients whose presentation retroperitoneal masses measured > 10 cm in diameter; three were resected showing complete necrosis, four resolved spontaneously within one year and nine (of whom one had radiotherapy) persisted for more than one year without evidence of relapse.
Thus, we conclude that there is little evidence to support adjuvant treatment after combination chemotherapy of advanced seminomas. Although a small proportion of patients will have residual seminoma after initial chemotherapy, it is usually reasonable to follow an observation policy reserving salvage treatment for clear evidence of recurrence.
